Clean Science and Technology Ltd. Financial Year 2025-26 Results

FY26 Revenue: Rs 9,565.47 million
PAT: Rs 2,296.55 million

Reader Takeaway: HALS business achieves breakeven; new plant commissioned amid industry headwinds.

What just happened

Clean Science and Technology Limited reported its financial results for the fiscal year 2025-26. The company's consolidated revenue from operations stood at Rs 9,565.47 million, a slight decrease from Rs 9,666.44 million in the previous year. Profit After Tax (PAT) for FY26 was Rs 2,296.55 million, down from Rs 2,644.05 million in FY25. EBITDA also saw a reduction, coming in at Rs 3,876.03 million compared to Rs 4,262.02 million in FY25.

The Board of Directors has proposed a final dividend of Rs 4 per equity share for FY 2025-26, subject to shareholder approval. This, combined with an interim dividend of Rs 2 per share, brings the total dividend payout for the year to Rs 6 per share.

Why this matters

Despite a challenging global chemical industry environment marked by pricing pressures and inventory corrections, Clean Science has made strategic progress. The achievement of EBITDA breakeven in the HALS business is a significant operational milestone. Furthermore, the commissioning of the Hydroquinone and Catechol plant is expected to contribute to future growth by improving raw material control and enabling downstream production.

The backstory

Clean Science and Technology has been focused on process innovation and disciplined capital allocation. The company has navigated a difficult financial year where many players in the chemical sector faced margin pressures. The HALS business's journey to breakeven and the new plant's successful integration highlight the company's operational resilience and strategic execution.

What changes now

The commissioning of the Hydroquinone and Catechol plant opens up a total addressable market of approximately Rs 4,200 crore. This new capacity is poised to enhance the company's product portfolio and potentially improve cost efficiencies. The Performance Chemicals 2 (PC2) project is slated for commercialization in FY 2026-27, indicating continued expansion plans.

Risks to watch

The primary risks revolve around the ongoing volatility in the global chemical industry, including persistent pricing pressures and competition. The successful and timely execution of the PC2 project is a critical factor for future growth. Management's voluntary decision to forgo a portion of their performance bonus underscores the challenging conditions faced.

Peer comparison

While the filing does not provide direct peer comparisons, the broader chemical industry has faced headwinds in FY26. Companies in this sector typically compete on product innovation, cost efficiency, and market access. Clean Science's focus on niche specialty chemicals and integrated manufacturing aims to differentiate it.

Context metrics (time-bound)

• HALS business achieved EBITDA breakeven in FY 2025-26 with approximately 3,200 tonnes volume.
• Hydroquinone and Catechol plant commissioned in December 2025.
• PC2 project targeted for commercialization in FY 2026-27.

What to track next

Investors will be keen to monitor the ramp-up of the Hydroquinone and Catechol plant's contribution to revenue and profitability. Progress on the PC2 project and the company's ability to manage costs and margins amidst industry challenges will be key.